Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2021 Earnings Results

Catalyst Pharmaceuticals Beats on EPS, Stock Down 1.75%

Catalyst Pharmaceuticals reported a strong EPS performance, exceeding expectations significantly. However, the stock fell by 1.75% on the day, likely due to the lack of revenue details and guidance. Investors may be cautious as they await more comprehensive financial insights in future reports.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.14	N/A	+47.37%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the earnings performance despite not providing specific revenue figures. They emphasized their commitment to strategic goals.

We are pleased with our EPS performance this quarter.

Our focus remains on executing our strategic initiatives.

Catalyst Pharmaceuticals Beats on EPS, Stock Down 1.75%

Key numbers

Management commentary

Catalyst Pharmaceuticals, Inc.

More earnings this week

Catalyst Pharmaceuticals Beats on EPS, Stock Down 1.75%

Key numbers

Management commentary